Mindfulness-assisted Psychedelic Therapy (MAPT)

This randomised, open-label, parallel arm trial (n=40) will examine the potential synergy between psilocybin (25mg) and mindfulness training in improving mental health.

Participants will be randomised into two groups: one receiving one 25mg dose of psilocybin combined with 8 weeks of mindfulness training, and the other receiving only psilocybin. The study aims to assess changes in depression symptoms, stress, and anxiety, as well as neurocognitive measures and blood inflammatory markers.

The primary outcome measure will be the change in self-reported depression symptoms on the CES-D scale from baseline to the 8-week follow-up. This study is conducted by the University of Southern California and is set to start in July 2024, with an estimated completion date in July 2026.

Topic Depression Anxiety
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.